< Back to previous page
Researcher
Isabelle Huys
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Responsible
From17 Dec 2020 → Today - Faculty of Law and Criminology (Faculty)
Member
From1 Oct 2014 → 30 Sep 2015 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today - Toxicology and Pharmacology (Division)
Member
From1 Oct 1999 → 9 Mar 2004
Projects
21 - 30 of 50
- From drug development to registration: optimalization of flow processesFrom10 Feb 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Central Repository for Digital PathologyFrom1 Feb 2021 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Global Omic Data Integration on Animal, Vegetal and Environment SectorsFrom1 Nov 2020 → TodayFunding: H2020-EU.2.1.-INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies (LEIT)
- CARE Corona Accelerated R&D in EuropeFrom1 Apr 2020 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market SustainabilityFrom16 Oct 2019 → 13 Dec 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- electronic Personalised Informed Consent (ePIC)From1 Oct 2019 → 30 Sep 2023Funding: BOF - projects
- Development, characterization and validation of an in vitro/in silico platform to predict transfer of medicines to human breast milk along with neonatal systemic exposure to maternal medication.From3 Sep 2019 → TodayFunding: FWO Strategic Basic Research Grant
- A Belgian policy framework for best-value biological medicinesFrom3 Sep 2019 → 18 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Rethinking access to medicines: towards a refined legal framework for medicine shortagesFrom1 Sep 2019 → 15 Mar 2022Funding: BOF - doctoral mandates, FWO fellowships
- Framework for value driven market access of gene therapyFrom1 Sep 2019 → 23 Oct 2020Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 213
- Testing and Practical Implementation of a User-Friendly Personalized and Long-Term Electronic Informed Consent Prototype in Clinical Research: Mixed Methods Study(2023)
Authors: David Geerts, Koen Yskout, Stef Verreydt, Pascal Borry, Liese Barbier, Isabelle Huys
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market Sustainability(2023)
Authors: Teresa Barcina Lacosta, Steven Simoens, Isabelle Huys
- A Belgian policy framework for best-value biological medicines(2023)
Authors: Yannick Vandenplas, Isabelle Huys, Steven Simoens, Arnold Vulto
- Balancing Innovation With Optimization in Oncology: Avenues for Bridging the Cancer Clinical Research Gap(2023)
Authors: Robbe Saesen, Isabelle Huys
- Cross-border clinical research in the EU: Fair allocation of data control and responsibility(2023)
Authors: Teodora Lalova-Spinks, Isabelle Huys, Peggy Valcke
- How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action(2023)
Authors: Rosanne Janssens, Liese Barbier, Elise Schoefs, Isabelle Huys
- The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis(2023)
Authors: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- Development of Cell and Gene Therapy Products: Implementation of a Blended Learning Approach(2023)
Authors: Isabelle Huys
Pages: 611 - 611 - Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments(2023)
Authors: Robbe Saesen, Isabelle Huys
- Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives(2023)
Authors: Rosanne Janssens, Elise Schoefs, Kristiaan Nackaerts, Isabelle Huys